Lab R&D Phase: 2012-2017

Our travel into trichomes started with Luis Matias Hernandez and his post-doc at Dr. Soraya Pelaz group in the Centre for Research in AgriGenomics, CRAG (2012-2014). His research was on trichome formation in different plants and their possible applications. In 2015, together with Sequentia Biotech funders, he received a Torres Quevedo grant by MINECO (Ministry of Economy, Industry and Competitiveness, Government of Spain) with the aim of trying to optimize medicinal plants using different biotechnology techniques.

After three years trying different methods, laboratory and controlled-greenhouse experiments finally gave very positive results. Luis was able to produce twice the artemisinin concentration in Artemisia annua leaves, as well as increasing the foliar or ‘leaf” biomass three times, all in all increasing the production of artemisinin six-fold. At the same time, he was able to accelerate the growth of Artemisia annua to just over 2 months instead of its usual 8 months, meaning that the production was increased from 3 to 5 times annually.

Based on these results, in 2016 we applied for and won the prestigious Neotec grant by CDTI (Centre for the Development of Industrial Technology from Spanish Government), which co-financed together with Sequentia Biotech the pilot production of our optimized Artemisia annua in the field through to the development of the final product prototype of Artennua. By the end of 2018 Biotech Tricopharming Research has been created and thanks to a tech-transfer agreement with Sequentia Biotech can continue MAPs (Medicinal and Aromatics Plants) R&D and commercializes Artennua® and its portfolio products.

Artennua Timeline
Pilot production of artemisia annua plants

Pilot Production Phase: 2017-2018

Currently we are in the Prototype-Product stage of Artennua, carrying out pilot production of the optimized plant in the field.

Our research revealed Tenerife as an optimal location to use our technology and cultivate Artennua. In 2017, we established a collaboration with the Instituto Canario de Investigaciones Agrarias (ICIA) to start pilot production tests in two different microclimates of the island. In May, we expect to begin pilot production of the optimized cultivate over 1 hectare of the most appropriate microclimate.

In summer we will have the first Artennua harvests and by the end of this year the final product in the form of dry, lyophilized leaves. We will also start scouting other potential formats of interest.

Initial Distribution: 2018-2019

Our 1-hectare agrofarm is situated in the north of the island of Tenerife, in Pico, Tejina, an ideal location for starting our small-scale production. For 3 months, starting June 2018, the farm has had to be renovated and prepared to meet current standards and develop the required infrastructure for the cultivation, harvest, post-harvest and transformation to product of Artennua. The different analyses to assess product quality have been subcontracted to the SEGAI, which provides research support to Universidad de la Laguna. The first beta tests are currently taking place by different European companies from the nutraceutical, animal health and natural cosmetics sectors.

Artennua product sample
Products on large scale production

Large Scale Production: 2019 onwards

Large-scale production of Artennua will begin in 2019. By the end of 2019 we have predicted that we will produce 12 tonnes of dry leaves per hectare and increase this amount in subsequent years as we plan to significantly expand the cultivation area.

We also hope to have established the necessary partnerships to produce Artennua extracts in a variety of formats, which could include the following:

  • Capsules containing purified extract from mature Artennua leaves
  • Capsules containing 99% pure artemisinin
  • Hydroalcoholic and glycolic extracts
  • Pulverized extract, dry or lyophilized, of mature Artennua leaves
  • Essential oils
  • Essential oil creams

We will perform quality control standards with the all the various formats to measure the content of any secondary metabolites that could be of potential interest.